CN1842329A - 伴随肝功能障碍的肝脏疾病的预防剂或改善剂 - Google Patents
伴随肝功能障碍的肝脏疾病的预防剂或改善剂 Download PDFInfo
- Publication number
- CN1842329A CN1842329A CNA2005800008604A CN200580000860A CN1842329A CN 1842329 A CN1842329 A CN 1842329A CN A2005800008604 A CNA2005800008604 A CN A2005800008604A CN 200580000860 A CN200580000860 A CN 200580000860A CN 1842329 A CN1842329 A CN 1842329A
- Authority
- CN
- China
- Prior art keywords
- fatty acid
- unsaturated fatty
- hepatic
- acid
- forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000019423 liver disease Diseases 0.000 title claims abstract description 49
- 230000003449 preventive effect Effects 0.000 title claims abstract description 22
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 154
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 151
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 85
- 239000000194 fatty acid Substances 0.000 claims description 85
- 229930195729 fatty acid Natural products 0.000 claims description 85
- 150000004665 fatty acids Chemical class 0.000 claims description 79
- 208000000857 Hepatic Insufficiency Diseases 0.000 claims description 61
- 206010019663 Hepatic failure Diseases 0.000 claims description 61
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 57
- 208000006454 hepatitis Diseases 0.000 claims description 45
- 235000013305 food Nutrition 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 39
- -1 alcohol ester Chemical class 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 37
- 235000005911 diet Nutrition 0.000 claims description 36
- 230000037213 diet Effects 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 244000005700 microbiome Species 0.000 claims description 26
- 231100000283 hepatitis Toxicity 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 22
- 230000006872 improvement Effects 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- XUJWOMMOEOHPFP-UHFFFAOYSA-N (all-Z)-8,11-Eicosadienoic acid Natural products CCCCCCCCC=CCC=CCCCCCCC(O)=O XUJWOMMOEOHPFP-UHFFFAOYSA-N 0.000 claims description 15
- XUJWOMMOEOHPFP-OKLKQMLOSA-N 8,11-Eicosadienoic acid Chemical compound CCCCCCCC\C=C\C\C=C\CCCCCCC(O)=O XUJWOMMOEOHPFP-OKLKQMLOSA-N 0.000 claims description 15
- ZMKDEQUXYDZSNN-OKLKQMLOSA-N 6E,9E-octadecadienoic acid Chemical compound CCCCCCCC\C=C\C\C=C\CCCCC(O)=O ZMKDEQUXYDZSNN-OKLKQMLOSA-N 0.000 claims description 12
- ZMKDEQUXYDZSNN-UHFFFAOYSA-N linolelaidic acid Natural products CCCCCCCCC=CCC=CCCCCC(O)=O ZMKDEQUXYDZSNN-UHFFFAOYSA-N 0.000 claims description 12
- KDYAPQVYJXUQNY-OPHDRXFHSA-N 1,2-di-(alpha-linolenoyl)-3-[alpha-D-galactosyl-(1->6)-beta-D-galactosyl]-sn-glycerol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDYAPQVYJXUQNY-OPHDRXFHSA-N 0.000 claims description 11
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 11
- 150000001982 diacylglycerols Chemical class 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 10
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 10
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 9
- 241000228212 Aspergillus Species 0.000 claims description 9
- 241000222290 Cladosporium Species 0.000 claims description 9
- 241001480517 Conidiobolus Species 0.000 claims description 9
- 241001480508 Entomophthora Species 0.000 claims description 9
- 241000223218 Fusarium Species 0.000 claims description 9
- 241000235575 Mortierella Species 0.000 claims description 9
- 241000235395 Mucor Species 0.000 claims description 9
- 241000228143 Penicillium Species 0.000 claims description 9
- 241000233614 Phytophthora Species 0.000 claims description 9
- 241000233639 Pythium Species 0.000 claims description 9
- 241000223252 Rhodotorula Species 0.000 claims description 9
- 241000233667 Saprolegnia Species 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 241001219832 Lobosporangium Species 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims 3
- 235000016709 nutrition Nutrition 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 abstract 1
- 235000014593 oils and fats Nutrition 0.000 description 26
- 239000000306 component Substances 0.000 description 23
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 241000907999 Mortierella alpina Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 3
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 3
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 231100000354 acute hepatitis Toxicity 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 235000012489 doughnuts Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- PZZKGQBMBVYPGR-UHFFFAOYSA-N η-tocopherol Chemical compound OC1=C(C)C=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 PZZKGQBMBVYPGR-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HNURKXXMYARGAY-UHFFFAOYSA-N 2,6-Di-tert-butyl-4-hydroxymethylphenol Chemical compound CC(C)(C)C1=CC(CO)=CC(C(C)(C)C)=C1O HNURKXXMYARGAY-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- GPLIMIJPIZGPIF-UHFFFAOYSA-N 2-hydroxy-1,4-benzoquinone Chemical compound OC1=CC(=O)C=CC1=O GPLIMIJPIZGPIF-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- OPAORDVBZRVVNQ-RNQWEJQRSA-N 4-[(z,2r)-4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbut-3-enyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](C)C(\C)=C/C=2C=C(OC)C(O)=CC=2)=C1 OPAORDVBZRVVNQ-RNQWEJQRSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102100034543 Fatty acid desaturase 3 Human genes 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000000377 Tussilago farfara Species 0.000 description 1
- 235000004869 Tussilago farfara Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- APFMQRLTJGOMPL-UHFFFAOYSA-N ethyl icosa-5,8,11-trienoate Chemical compound CCCCCCCCC=CCC=CCC=CCCCC(=O)OCC APFMQRLTJGOMPL-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical class O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000020601 preterm formula Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
提供了以ω-9不饱和脂肪酸为活性成分的用于伴随肝功能障碍的肝脏疾病的预防剂或改善剂。
Description
技术领域
本发明涉及以ω-9不饱和脂肪酸为活性成分或以ω-9不饱和脂肪酸为组成脂肪酸的化合物为活性成分的针对伴随肝功能障碍的肝脏疾病的预防剂或改善剂、涉及对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,并涉及其制备方法。更具体地,本发明涉及以选自ω-9不饱和脂肪酸、ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯、三酰甘油酯和磷脂中的至少之一为活性成分的针对伴随肝功能障碍的急性或慢性肝炎、急性肝功能衰竭、肝硬变和/或肝细胞癌的预防剂或改善剂、涉及具有预防或改善作用的组合物或饮食,并涉及其制备方法。
背景技术
由于病毒或多种毒性物质等造成的肝细胞破坏发展而来的肝功能障碍为引起急性或慢性肝炎、进一步地为引起肝硬变、肝细胞癌等的原因。尤其是急性肝炎与普通肝炎相比,前者存在自觉症状如恶心、呕吐、倦怠感等剧烈、高烧、白细胞数增多、CRP强阳性、黄疸也急剧变坏,已知有时导致成年前死亡。另外,即使没有成年前死亡,从慢性肝炎到肝硬变、肝细胞癌的病例极多,形成了极多的社会问题。
从肝炎的原因来看,特异性感染肝细胞的病毒(甲型肝炎病毒、乙型肝炎病毒、丙型肝炎病毒、丁型肝炎病毒、戊型肝炎病毒)为主要引起急性肝炎的原因,其中丙型病毒性肝炎占日本慢性肝病原因的大半,实际上占肝细胞癌原因的90%。由于自身免疫机制引起的肝功能障碍称为自身免疫性肝病,其除了自身免疫性肝炎外,还包括原发性胆汁性肝硬变(PBC)、原发性硬化性胆管炎(PSC)及其相关疾病。
醇类主要经肝脏代谢,慢性摄入醇类对肝脏的多种代谢系统产生影响,从而引起高尿酸血症、高脂血症、高乳酸血症等。脂肪酸的代谢障碍引起中性脂肪的蓄积、刺激炎性细胞并引发肝炎,有时大量饮酒导致称为重症醇性肝炎的预后不良的急性肝功能衰竭。肝细胞中脂肪的蓄积起因于饮酒而产生的醇性或肥胖引起的营养过剩,这通常不会导致肝炎,但据报道有时伴随着类似醇性肝炎的炎症,偶尔最终引起肝硬变的例子。
肝硬变为所有慢性肝功能障碍的最终结果。在肝细胞障碍与再生的长期重复过程中,形成了肝脏的纤维化和再生结节。因此,表现出慢性肝功能障碍的所有肝脏疾病显示出肝细胞功能不全和门脉压亢进。在日本约40万肝硬变患者的病因几乎都是病毒性的,特别是由丙型肝炎病毒引起的为62%,由乙型肝炎病毒引起的为15%。病毒性肝硬变中肝细胞癌的发生率高,这极大影响肝硬变的预后。其他的病因有醇、药物及毒性物质、自身免疫、胆汁郁滞、循环障碍、代谢异常、寄生虫等。
作为治疗方法,对于可避免的病因(醇性、药剂型)避免病因是最重要的,对于病毒性(HBV、HCV)而言目前的治疗法仅为干扰素,其对HBV的效果几乎不可期待,对HCV的效果仅为30%至50%。最近,新研发出对于慢性乙型肝炎可与拉米夫定(lamivudine)(抗病毒剂)联用,对于慢性丙型肝炎可与利巴韦林(ribavirin)(抗病毒剂)联用。另一方面,对于不能清除病毒的病例,为了减缓肝损坏并抑制向肝硬变的发展,作为癌的二次或一次预防目的,可施与糖皮质激素、甘草皂甙制品、熊去氧胆酸等(药局Vol.54,增刊号,2003)。因此,当前以辅助治疗的肝保护疗法为主体,尚无无副作用的有效肝炎治疗剂和肝炎诱发抑制剂(Medical Digest;卷39(4):1990)。
发明公开
因此,非常希望研发出可预防或改善伴随肝功能障碍的肝脏疾病并与食物很好适应的副作用小的化合物。
本发明者们为了解决上述课题进行了大量研究,结果发现了显示极好的抑制肝功能障碍作用、预防或改善伴随肝功能障碍的肝脏疾病、显示极好的食品适应的ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物,从而完成了本发明。因此,本发明者们提供了以ω-9不饱和脂肪酸为活性成分或以ω-9不饱和脂肪酸为组成脂肪酸的化合物为活性成分的针对伴随肝功能障碍的肝脏疾病的预防剂或改善剂、提供了对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,并提供了其制备方法。
更具体地,本发明提供了以选自ω-9不饱和脂肪酸、ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯、三酰甘油酯和磷脂中的至少之一为活性成分的、针对伴随肝功能障碍的急性或慢性肝炎、急性肝功能衰竭、肝硬变和/或肝细胞癌的预防剂或改善剂;提供了具有预防或改善作用的组合物或饮食,并提供了其制备方法。
附图简述:
图1为显示蜜酸(mead acid)对半乳糖胺肝功能障碍中肝功能标志物的效果图。图中对照代表对照食物组,N-3代表DHA食物组,N-9代表蜜酸食物组。施用GalN/LPS的组为每组15只小鼠,施用生理盐水的组为每组3只小鼠。
图2为显示蜜酸对半乳糖胺肝功能障碍中生存率的效果图。图中对照代表对照食物组,N-3代表DHA食物组,N-9代表蜜酸食物组。每组各使用10只小鼠。
实施发明的最佳实施方式
本发明涉及以ω-9不饱和脂肪酸为活性成分或以ω-9不饱和脂肪酸为组成脂肪酸的化合物为活性成分的针对伴随肝功能障碍的肝脏疾病的预防剂或改善剂、涉及对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,并涉及其制备方法。本发明的活性成分ω-9不饱和脂肪酸是指与脂肪酸的甲基端最接近的双键位于自甲基开始数的第9位碳和第10位碳之间,具有2个或以上双键,优选地具有18至22个碳原子数,可包括例如6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)和5,8,11-二十碳三烯酸(20:3 ω9)等,它们可分别单独使用或组合使用。
另外,由于天然存在的ω-9不饱和脂肪酸均为顺式,本发明优选使用顺式的ω-9不饱和脂肪酸。
已知ω-9不饱和脂肪酸中如5,8,11-二十碳三烯酸(20:3 ω9,也称为蜜酸(mead acid))和8,11-二十碳二烯酸(20:2 ω9)可作为缺乏必需脂肪酸的动物组织的组成脂肪酸之一而存在。
这些不饱和脂肪酸在体内可成为白三烯3类的前体,其生理活性是很有前景的,已发明了“用白三烯B4(LTB4)作为医学疾病的预防剂和改善剂”(特开平07-041421)、“介导迟发型超敏反应的医学疾病的预防剂和改善剂”(特开平08-053349)、“引起软骨组织异常的疾病的预防药或治疗药”(WO97-05863),报道了其适用于抗炎、抗过敏、抗关节炎和变形性关节病。然而,根据现有技术,不能预见其对伴随肝功能障碍的肝脏疾病的预防作用,而本发明首次使用本发明的肝功能障碍模型动物评估而明确。
本发明的活性成分为ω-9不饱和脂肪酸,并且可使用以ω-9不饱和脂肪酸为组成脂肪酸的所有化合物。对于以ω-9不饱和脂肪酸为组成脂肪酸的化合物,可以游离脂肪酸形式使用,也可包括可药用的ω-9不饱和脂肪酸盐,如钠盐、钾盐、锂盐或其它的碱金属盐、锌盐、钙盐、镁盐等。另外,可例举ω-9不饱和脂肪酸的低级醇酯如ω-9不饱和脂肪酸甲酯、ω-9不饱和脂肪酸乙酯等。此外,可使用以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯、三酰甘油酯、磷脂和糖酯等。另外,本发明不限于上述,可利用以ω-9不饱和脂肪酸为组成脂肪酸的所有化合物。
本发明使用的ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物可为任何来源。即,它们可来自能产生ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物的微生物,其也可由缺乏必需脂肪酸的动物组织、缺乏必需脂肪酸的动物培养细胞产生,也可通过化学或酶法合成,另外也可从天然物质如自动物软骨提取、分离和纯化而产生。
但是,考虑到应用于食品时,ω-9不饱和脂肪酸优选地为单酰甘油酯、二酰甘油酯、三酰甘油酯或磷脂的形式,特别优选地为三酰甘油酯的形式。虽然不存在包含ω-9不饱和脂肪酸的三酰甘油酯(与含有的部分或全部组成脂肪酸为ω-9不饱和脂肪酸的三酰甘油酯同义)的丰富来源,本发明者们使得以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯可工业应用。通过提供肝功能障碍模型动物,首次阐明了本发明活性成分的效果,明确了对伴随肝功能障碍的肝脏疾病具有预防或改善效果。
可产生包含ω-9不饱和脂肪酸的油脂(三酰甘油酯)的微生物例如为通过对属于被孢霉属(Mortierella)、耳霉属(Conidiobolus)、腐霉属(Pythium)、疫霉属(Phytophthora)、青霉属(Penicillium)、枝孢属(Cladosporium)、毛霉属(Mucor)、镰孢属(Fusarium)、曲霉属(Aspergillus)、红酵母属(Rhodotorula)、虫霉属(Entomophthora)、刺孢囊霉属(Echinosporangium)、水霉属(Saprolegnia)的并可产生花生四烯酸的微生物进行突变处理而得到的Δ12去饱和活性低下或缺乏的微生物。
可产生花生四烯酸的微生物能从作为培养基成分的碳源生物合成硬脂酸(18:0),硬脂酸在Δ9去饱和酶的作用下转化为油酸(18:1 ω9),油酸在Δ12去饱和酶的作用下转化为亚油酸(18:2 ω6),亚油酸在Δ6去饱和酶的作用下转化为γ-亚麻酸(18:3 ω6),γ-亚麻酸在延伸酶的作用下转化为二高γ-亚麻酸(20:3 ω6),二高γ-亚麻酸在Δ5去饱和酶的作用下转化为花生四烯酸(20:4 ω6)。但是,当阻断Δ12去饱和酶时,由Δ6去饱和酶自油酸生物合成产生6,9-十八碳二烯酸(18:2 ω9),在延伸酶的作用下自6,9-十八碳二烯酸生物合成产生8,11-二十碳二烯酸(20:2 ω9),然后在Δ5去饱和酶的作用下自8,11-二十碳二烯酸生物合成产生5,8,11-二十碳三烯酸(20:3 ω9)。
具体地,作为可产生包含ω-9不饱和脂肪酸的油脂(三酰甘油酯)的微生物,包括但不限于通过对特开平5-91888号所述的可产生花生四烯酸的微生物进行突变处理而得到的、具有Δ5去饱和酶活性和Δ6去饱和酶活性且Δ12去饱和酶活性低下或缺乏的微生物,例如高山被孢霉(Mortierellaalpina)SAM1861(FERM BP-3590)(根据布达佩斯条约进行的国际保藏,于1991年9月30日保藏于独立行政法人产业技术综合研究所专利生物保藏中心(茨城县筑波市东1丁目1号1中央第6));进一步地,对可产生花生四烯酸的微生物进行突变处理而得到的、Δ12去饱和酶活性低下或缺乏且在具有Δ5去饱和活性、Δ6去饱和活性和/或链延伸活性中的至少之一得以提高的微生物,例如高山被孢霉SAM2086(FERM BP-6032)(根据布达佩斯条约进行的国际保藏,于1996年8月5日保藏于独立行政法人产业技术综合研究所专利生物保藏中心(茨城县筑波市东1丁目1号1中央第6))(自1996年8月5日保藏的国内保藏FERM P-15766于1997年7月30日转移为国际保藏)。
为了培养用于本发明的菌株,将所述菌株的胞子、菌丝或预培养得到的预培养液接种至液体培养基或固体培养基并培养。当为液体培养基时,作为碳源可使用通常使用的任一碳源,包括但不限于葡萄糖、果糖、鼠李糖、蔗糖、麦芽糖、可溶性淀粉、糖蜜、甘油和甘露糖醇等。
作为氮源,可使用蛋白胨、酵母提取物、麦芽提取物、肉膏、酪蛋白氨基酸、玉米浆、大豆蛋白、脱脂大豆、棉籽碾碎物等天然氮源、尿素等有机氮源、以及硝酸钠、硝酸铵、硫酸铵等无机氮源。此外,根据需要,可将磷酸盐、硫酸镁、硫酸铁、硫酸铜等无机盐和维生素等作为微量营养源使用。对这些培养基成分只要不为损害微生物生长的浓度,并无特定的限制。实践中,碳源的总添加量通常为0.1至40重量%,优选地为1至25重量%,氮源的总添加量通常为0.1至20重量%,优选地为1至10重量%,可在培养开始时或在培养过程中为了达到总碳源量和总氮源量而添加碳源及氮源。
ω-9不饱和脂肪酸产生菌的培养温度虽然取决于所使用的微生物,但可在5至40℃,优选地在20至30℃,或在20至30℃培养使菌体增殖然后在5至20℃继续培养,从而产生不饱和脂肪酸。通过这样的温度管理,所产生的脂肪酸中高度不饱和脂肪酸的比例可上升。培养基的pH为4至10,优选地为5至9,通过通气搅拌培养、振荡培养或静置培养进行。培养通常进行2至30天,优选地为5至20天,更优选地进行5至15天。
进一步地,作为提高含有ω-9不饱和脂肪酸的油脂(三酰甘油酯)中ω-9不饱和脂肪酸比例的方法,可对含有ω-9不饱和脂肪酸的油脂进行选择性加水分解而得到高含有ω-9不饱和脂肪酸的油脂。所述选择性加水分解所使用的脂肪酶对三酰甘油酯不具有位置特异性,由于加水分解活性与双键数成反比,不为高度不饱和脂肪酸的脂肪酸酯键被加水分解。这样,所产生的PUFA部分甘油酯间的酯交换反应等产生高度不饱和脂肪酸提高的三酰甘油酯(Enzymatic Fractionation and Enrichment of n-9 PUFA,J.Am.Oil Chem.Soc.,80,37-42(2003))。
因此,可将对含有ω-9不饱和脂肪酸的油脂(三酰甘油酯)进行选择性加水分解而得到的高含有ω-9不饱和脂肪酸的油脂(三酰甘油酯)作为本发明的活性成分。相对于含有本发明ω-9不饱和脂肪酸的油脂(三酰甘油酯)的总脂肪酸,ω-9不饱和脂肪酸的比率优选地高,以排除其他脂肪酸的影响,其中所述ω-9不饱和脂肪酸具体而言为至少一种或一种以上选自6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)及5,8,11-二十碳三烯酸(20:3 ω9)的ω-9不饱和脂肪酸。
然而,本发明不限于高比率,在实际中,当应用于食品时有时会碰上ω-9不饱和脂肪酸的绝对量,基本上可使用含有ω-9不饱和脂肪酸20%重量或以上,优选地30%重量或以上,更优选地40%重量或以上的油脂(三酰甘油酯)。进一步地,基本上可使用含有5,8,11-二十碳三烯酸(20:3 ω9)10%重量或以上,优选地20%重量或以上,更优选地30%重量或以上的油脂(三酰甘油酯)。
自可产生ω-9不饱和脂肪酸的微生物的培养菌体开始,通过菌体破坏,根据需要使干燥,用有机溶剂例如正己烷等进行提取处理或通过用超临界碳酸气提取处理可获得含有ω-9不饱和脂肪酸的油脂。另外,对上述油脂进行加水分解和酯化操作可获得含有ω-9不饱和脂肪酸的游离脂肪酸混合物或脂肪酸酯混合物。接下来,对上述游离脂肪酸混合物或脂肪酸酯混合物通过常规的尿素分级法、液液分配色谱、柱层析等,可获得纯度80%或以上的游离脂肪酸6,9-十八碳二烯酸、8,11-二十碳二烯酸及5,8,11-二十碳三烯酸以及脂肪酸酯。
另外,本发明的活性成分ω-9不饱和脂肪酸不必限于高纯度的纯化品,也可使用以ω-9不饱和脂肪酸为组成脂肪酸的化合物,具体而言为含有ω-9不饱和脂肪酸的单酰甘油酯、二酰甘油酯、三酰甘油酯、磷脂和糖脂。此外,可将以ω-9不饱和脂肪酸为组成脂肪酸的化合物单独使用或与含有ω-9不饱和脂肪酸的游离脂肪酸混合物或脂肪酸酯混合物组合使用。
本发明涉及以ω-9不饱和脂肪酸为活性成分或以ω-9不饱和脂肪酸为组成脂肪酸的化合物为活性成分的针对伴随肝功能障碍的肝脏疾病的预防剂或改善剂、涉及对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,并涉及其制备方法。作为本发明对象的伴随肝功能障碍的肝脏疾病,可列举如病毒性肝炎、药物性肝炎、醇性肝炎或脂肪型肝炎等引起的急性肝炎或慢性肝炎等。进一步地,作为考虑了这些肝炎发展而发病的疾病,可列举急性肝功能衰竭、肝硬变、肝细胞癌等。
对伴随肝功能障碍的肝脏疾病具有预防或改善作用的饮食的制备方法中,可将ω-9不饱和脂肪酸和/或以ω-9不饱和脂肪酸为组成脂肪酸的化合物单独使用,或与基本上不含有ω-9不饱和脂肪酸的饮食原料或与既使含有也仅含有少量ω-9不饱和脂肪酸的饮食原料组合使用。
特别地,在组成脂肪酸的部分或全部为ω-9不饱和脂肪酸的三酰甘油酯的情况下,油脂(三酰甘油酯)可用于无数种用途,可作为食品、饮料、化妆品、医药品的原料和添加物。因此,对其使用目的、使用量无任何限制。
例如,作为食品组合物,除了一般食品外,可例举功能性食品、营养品、补助食品、早产儿配方奶、婴幼儿配方奶、婴幼儿食品、孕产妇食品或老人用食品等。此外,根据医生的处方在营养师的管理下,在医院调配饭食时可向任一食品中加入本发明的ω-9不饱和脂肪酸和/或以ω-9不饱和脂肪酸为组成脂肪酸的化合物,以当场制备好的食品形式施与患者。
作为含油脂的食品例如有肉、鱼和坚果等本身含有油脂的天然食品、汤等在烹调时加入了油脂的食品、油炸圈饼(donut)等作为热介质而使用油脂的食品、奶油等油脂食品、小甜饼干等加工时加入油脂的加工食品、或硬饼干等加工结束时喷或涂上油脂的食品。进一步地,可将油脂添加至不含油脂的农产品、发酵食品、畜产品、水产品或饮料中。进一步地,它们可为功能性产品或药品的形式,例如可为经肠营养剂、粉末剂、颗粒剂、片剂、内服液、悬液、乳液、糖浆等加工形式。
另外,本发明的组合物除了含有本发明的活性成分外,还可含有通常在饮食品、药品或准药品中使用的多种载体或添加物。特别优选地含有防止本发明的活性成分氧化的抗氧化剂。抗氧化剂包括例如生育酚、黄酮衍生物、叶甜素、曲酸、没食子酸衍生物、儿茶酸、款冬酸、棉酚、吡嗪衍生物、芝麻酚、愈创木酚、愈创木酸、对香豆酸、去甲二氢愈创木酸、固醇类、萜类、核酸碱基类、类胡萝卜素类和木素类等天然抗氧化剂、以及以抗坏血酸-棕榈酸酯、抗坏血酸-硬脂酸酯、丁基羟基苯甲醚(BHA)、丁基羟基甲苯(BHT)、单-叔丁基羟基醌(TBHQ)和4-羟甲基-2,6-二叔丁基酚(HMBP)为代表的合成抗氧化剂。
在生育酚中,作为相关化合物,可提及α-生育酚、β-生育酚、γ-生育酚、δ-生育酚、ε-生育酚、ξ-生育酚、η-生育酚和生育酚酯(生育酚乙酸酯等)以及生育三烯酚。在类胡萝卜素中可提及例如β-胡萝卜素、角黄素、虾青素等。
本发明的组合物除了包含本发明的活性成分外,还可包含作为载体的多种载体、补充剂、稀释剂、填充剂、分散剂、赋形剂、结合剂溶剂(如水、乙醇、植物油)、助溶剂、缓冲剂、溶解促进剂、胶凝剂、混悬剂、小麦粉、米粉、淀粉、玉米淀粉、多糖、乳蛋白、胶原、米油、卵磷脂等。作为添加剂,包括但不限于例如维生素类、甜味剂、有机酸、着色剂、香料、防湿剂、纤维、电解质、矿物质、营养素、抗氧化剂、防腐剂、芳香剂、湿润剂、天然食物提取物、蔬菜提取物等。
当本发明的活性成分实际应用于饮食品时,食品中混合的ω-9不饱和脂肪酸的绝对量也变得重要。但是,在食品中混合的绝对量也随所混合的饮食品的摄取量而变化,因此当将含有组成脂肪酸的一部分或全部为ω-9不饱和脂肪酸的三酰甘油酯的三酰甘油酯与食品混合时,以ω-9不饱和脂肪酸的量为0.001重量%或以上、优选地0.01重量%或以上、更优选地0.1重量%或以上进行混合。进一步地,对5,8,11-二十碳三烯酸,可使用0.0003重量%或以上、优选地0.003重量%或以上、更优选地0.03重量%或以上,并且根据常规的制备法进行加工制备。
以对伴随肝功能障碍的疾病的预防改善或健康维持为目的,作为标准,将含有本发明的脂肪酸的饮食品以每天经口摄入本发明的脂肪酸0.001g至10g,优选地0.001g至5g,更优选地0.001g至2g。
本发明的组合物作为药品使用时,可按照制剂技术领域惯用的方法如日本药典中所记载的方法或根据所述方法的方法制造。
本发明的组合物作为药品使用时,对组合物中的活性成分的混合量没有特别的限制,只要能达到本发明的目的即可,可使用合适的混合比例。
本发明的组合物作为药品使用时,可以为任何剂型,只要经口施与或非经口施与可行即可,例如可列举注射剂、输注液、散剂、颗粒剂、锭剂、胶囊剂、肠溶剂、片剂、内用液剂、悬浮剂、乳剂、糖浆剂、外用液剂、湿布剂、滴鼻剂、滴耳剂、滴眼剂、吸入剂、软膏剂、洗剂、坐剂等,它们可根据相应的症状分别使用,特别地,优选经口施与。这些制剂可按照常规方法根据目的在主要成分中使用已知的辅助剂进行制剂,其中所述已知的辅助剂为稳定剂、防氧化剂、赋形剂、结合剂、崩解剂、润滑剂、矫味剂等在药物的制剂技术领域通常可使用的辅助剂。
本发明的组合物的施与量根据年龄、体重、症状、施与次数等而不同,例如成人(约60kg)一天施用本发明的ω-9不饱和脂肪酸和/或以ω-9不饱和脂肪酸为组成脂肪酸的化合物以ω-9不饱和脂肪酸换算通常约0.001g至20g,优选地0.01g至10g,更优选地0.05g至5g,最优选地0.1g至2g,一日1次-3次施与。进一步地,以5,8,11-二十碳三烯酸换算通常约0.0001g至10g,优选地0.001g至5g,更优选地0.01g至2g,最优选地0.05g至2g,一日1次-3次施与。
知道了本发明的活性成分脂肪酸为在生物体内缺乏必需脂肪酸的状态下被生物合成的生物体组分。通过对7周龄的ICR雄性小鼠以2g/kg/天连续施与(经口施与)2周,没有观察到任何异常的症状,可见在安全性方面也是良好的。
实施例:
下面通过实施例对本发明进一步具体地说明。但是,本发明不限于这些实施例。
参考例1以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯的制备方法
将含有4%葡萄糖和1%酵母提取物的培养基(pH6.0)5L置于10L发酵罐中,于120℃灭菌30分钟。接种高山被孢霉(Mortierella alpina)的突变株SAM1861或SAM2086的100ml预培养液,通气量1vvm,搅拌数为300转/分钟,进行8天的通气搅拌培养。培养温度为:培养开始时为28℃,自培养第2天下降至20℃。培养的第1至4天,每天添加1%的葡萄糖。
培养结束后,通过过滤、干燥回收具有以ω-9不饱和脂肪酸为组成脂肪酸的菌体,自得到的菌体通过己烷提取获得油脂,经过食用油脂的纯化步骤(脱胶、脱酸、脱味、脱色)得到含有ω-9不饱和脂肪酸的三酰甘油酯(ω-9不饱和脂肪酸在三酰甘油酯的任一位置处结合)。
将得到的油脂(三酰甘油酯)甲酯化,对得到的脂肪酸甲酯气相色谱分析时,培养SAM1861株可得到6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)和5,8,11-二十碳三烯酸(20:3 ω9)占总脂肪酸比例分别为12.94%、3.29%、16.38%;培养SAM2086株可得到6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)和5,8,11-二十碳三烯酸(20:3 ω9)占总脂肪酸比例分别为12.41%、3.58%、20.87%。
进一步地,将上述含有ω-9不饱和脂肪酸的油脂(三酰甘油酯)乙酯化,因为为含有20%5,8,11-二十碳三烯酸乙酯的脂肪酸乙酯混合物,通过常规的高效液相色谱,可以分离纯化98%纯度的5,8,11-二十碳三烯酸乙酯。
实施例1通过肝功能障碍模型动物评价含有ω-9不饱和脂肪酸的油脂1
将8%棕榈油(对照食物)添加至市售饲料、将参考例1制备的6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)和5,8,11-二十碳三烯酸(20:3 ω9)占总脂肪酸比例分别为12.94%、3.29%、16.38%的比例形成组成脂肪酸的油脂SUNTGM178%(蜜酸食物)添加至市售饲料、以及将含有22%DHA的鱼油5%和三油精甘油酯3%的混合物(DHA食物)添加至市售饲料,施与4周龄雄性ddY品系小鼠3周后,使用生理盐水溶解D-半乳糖胺和脂多糖分别至800mg/kg和25μg/kg,将它们混合(GalN/LPS)并腹膜内施用。施用GalN/LPS 6周后取血,分离血清,测定血清中GPT、GOT活性,确认了虽然施用GalN/LPS使得诱发了肝功能障碍,GPT、GOT活性上升,但蜜酸食物组与对照食物组和DHA食物组相比GPT、GOT活性显著性降低,蜜酸明显地可抑制肝功能障碍,该抑制效果较DHA强(图1)。
实施例2通过肝功能障碍模型动物评价含有ω-9不饱和脂肪酸的油脂2
将8%棕榈油(对照食物)添加至市售饲料、与实施例1同样的SUNTGM17 8%(蜜酸食物)添加至市售饲料、以及将含有22%DHA的鱼油5%和三油精甘油酯3%的混合物(DHA食物)添加至市售饲料,施与4周龄雄性ddY品系小鼠3周后,使用生理盐水溶解D-半乳糖胺和脂多糖分别至800mg/kg和75μg/kg,将它们混合(GalN/LPS)并腹膜内施用。施用GalN/LPS后,每隔1小时调查生存数,直至24小时后。计算生存率时,蜜酸食物组的生存率明显高于对照组和DHA食物组(图2)。
实施例3通过肝功能障碍模型动物评价5,8,11-二十碳三烯酸乙酯
自参考例1制备的油脂SUNTGM17纯化的5,8,11-二十碳三烯酸乙酯(蜜酸)10mg/kg经口施用1周后,使用生理盐水溶解D-半乳糖胺和脂多糖分别至800mg/kg和25μg/kg,将它们混合(GalN/LPS)并腹膜内施用。施用GalN/LPS 6周后取血,分离血清,测定血清中GPT、GOT活性,在对照食物组中GOT活性为1024±94IU/L,与之相比蜜酸施与组为413±37IU/L,认为其可显著性抑制肝功能障碍。
实施例4制备胶囊
向明胶100重量份和食品添加剂甘油35重量份中加水,50至60℃溶解,制备粘度2000cp的明胶包衣。接下来,向自参考例1制备的以ω-9不饱和脂肪酸为组成脂肪酸的油脂(三酰甘油酯)混合0.05重量%的维生素E油,制备内容物1。然后向参考例1获得的98%5,8,11-二十碳三烯酸乙酯混合维生素E油0.05重量%,制备内容物2。使用这些内容物1和2,通过常规方法进行胶囊化和干燥,制备1粒中含有200mg内容物的软胶囊。
实施例5用于脂肪输注液中
加入参考例1获得的以ω-9不饱和脂肪酸为组成脂肪酸的油脂(三酰甘油酯)400g、纯化的卵黄卵磷脂48g、油酸20g、甘油100g和0.1N氢氧化钠40ml,使用匀浆器分散后,加入注射用蒸馏水至4L。将其使用高压喷雾式乳化器进行乳化,制备脂质乳液。将每200ml该脂质乳液分注入塑料袋中后,于121℃20分钟进行高压蒸汽灭菌处理,成为脂肪输注液。
实施例6用于汁液中
将2gβ-环糊精添加至20%的乙醇水溶液20ml中,边用搅拌器搅拌边向其中加入参考例1获得的以ω-9不饱和脂肪酸为组成脂肪酸的油脂(三酰甘油酯)(混合有0.05重量%的维生素E)100mg,50℃孵育2小时。室温冷却(约1小时)后,接下来于搅拌的同时在4℃孵育10小时。通过离心回收所产生的沉淀,用正己烷洗净后,进行冷冻干燥,获得含有以ω-9不饱和脂肪酸为组成脂肪酸的油脂(三酰甘油酯)的环糊精包接物1.8g。将该粉末1g均匀混合至10L汁液中,制备了含有以ω-9不饱和脂肪酸为组成脂肪酸的油脂(三酰甘油酯)的汁液。
Claims (46)
1.伴随肝功能障碍的肝脏疾病的预防剂或改善剂,其包含ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物。
2.根据权利要求1所述的伴随肝功能障碍的肝脏疾病的预防剂或改善剂,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的化合物是ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯和/或三酰甘油酯、或者磷脂。
3.根据权利要求2所述的伴随肝功能障碍的肝脏疾病的预防剂或改善剂,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是ω-9不饱和脂肪酸相对于组成所述三酰甘油酯的总脂肪酸含有20%或以上。
4.根据权利要求1-3中任意一项所述的伴随肝功能障碍的肝脏疾病的预防剂或改善剂,其中所述ω-9不饱和脂肪酸为至少一种选自6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)及5,8,11-二十碳三烯酸(20:3 ω9)的ω-9不饱和脂肪酸。
5.根据权利要求1-4中任意一项所述的伴随肝功能障碍的肝脏疾病的预防剂或改善剂,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是通过对属于被孢霉属(Mortierella)、耳霉属(Conidiobolus)、腐霉属(Pythium)、疫霉属(Phytophthora)、青霉属(Penicillium)、枝孢属(Cladosporium)、毛霉属(Mucor)、镰孢属(Fusarium)、曲霉属(Aspergillus)、红酵母属(Rhodotorula)、虫霉属(Entomophthora)、刺孢囊霉属(Echinosporangium)、水霉属(Saprolegnia)的并可产生花生四烯酸的微生物进行突变处理而得到的Δ12去饱和活性低下或缺乏的微生物在培养基中培养,并自培养物提取而得到的。
6.根据权利要求1-5中任意一项所述的预防剂或改善剂,其中所述伴随肝功能障碍的肝脏疾病为急性或慢性肝炎。
7.根据权利要求1-5中任意一项所述的预防剂或改善剂,其中所述伴随肝功能障碍的肝脏疾病为急性肝功能衰竭、肝硬变和/或肝细胞癌。
8.对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,其包含ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物。
9.权利要求8所述的对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的化合物是ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯和/或三酰甘油酯、或者磷脂。
10.权利要求9所述的对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯为ω-9不饱和脂肪酸相对于构成所述三酰甘油酯的总脂肪酸含有20%或以上。
11.根据权利要求8-10中任意一项所述的对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,其中所述ω-9不饱和脂肪酸为至少一种选自6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)及5,8,11-二十碳三烯酸(20:3 ω9)的ω-9不饱和脂肪酸。
12.根据权利要求8-11中任意一项所述的对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是通过对属于被孢霉属、耳霉属、腐霉属、疫霉属、青霉属、枝孢属、毛霉属、镰孢属、曲霉属、红酵母属、虫霉属、刺孢囊霉属、水霉属的并可产生花生四烯酸的微生物进行突变处理而得到的Δ12去饱和活性低下或缺乏的微生物在培养基中培养,并自培养物提取而得到的。
13.根据权利要求8-12中任意一项所述的具有预防或改善作用的组合物或饮食,其中所述伴随肝功能障碍的肝脏疾病为急性或慢性肝炎。
14.根据权利要求8-12中任意一项所述的具有预防或改善作用的组合物或饮食,其中所述伴随肝功能障碍的肝脏疾病为急性肝功能衰竭、肝硬变和/或肝细胞癌。
15.根据权利要求8-14中任意一项所述的对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食,其中所述饮食为功能性食品、营养补助食品、特定的保健用食品或老人用食品。
16.制备对伴随肝功能障碍的肝脏疾病具有预防或改善作用的饮食的方法,其特征在于:将ω-9不饱和脂肪酸和/或以ω-9不饱和脂肪酸为组成脂肪酸的化合物与基本上不含有或仅含有少量ω-9不饱和脂肪酸的饮食原料混合。
17.对伴随肝功能障碍的肝脏疾病的预防方法或改善方法,其包括将ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物施与受试对象。
18.权利要求17所述的方法,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的化合物是ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯和/或三酰甘油酯、或者磷脂。
19.权利要求18所述的方法,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是ω-9不饱和脂肪酸相对于组成所述三酰甘油酯的总脂肪酸含有20%或以上。
20.权利要求17-19中任意一项所述的方法,其中所述ω-9不饱和脂肪酸为至少一种选自6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)及5,8,11-二十碳三烯酸(20:3 ω9)的ω-9不饱和脂肪酸。
21.权利要求17-20中任意一项所述的方法,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是通过对属于被孢霉属、耳霉属、腐霉属、疫霉属、青霉属、枝孢属、毛霉属、镰孢属、曲霉属、红酵母属、虫霉属、刺孢囊霉属、水霉属的并可产生花生四烯酸的微生物进行突变处理而得到的Δ12去饱和活性低下或缺乏的微生物在培养基中培养,并自培养物提取而得到的。
22.权利要求17-21中任意一项所述的方法,其中所述伴随肝功能障碍的肝脏疾病为急性或慢性肝炎。
23.权利要求17-21中任意一项所述的方法,其中所述伴随肝功能障碍的肝脏疾病为急性肝功能衰竭、肝硬变和/或肝细胞癌。
24.对伴随肝功能障碍的肝脏疾病的预防方法或改善方法,其包括施与包含ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物的组合物或饮食。
25.权利要求24所述的方法,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的化合物是ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯和/或三酰甘油酯、或者磷脂。
26.权利要求25所述的方法,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是ω-9不饱和脂肪酸相对于组成所述三酰甘油酯的总脂肪酸含有20%或以上。
27.权利要求24-26中任意一项所述的方法,其中所述ω-9不饱和脂肪酸为至少一种选自6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)及5,8,11-二十碳三烯酸(20:3 ω9)的ω-9不饱和脂肪酸。
28.权利要求24-27中任意一项所述的方法,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是通过对属于被孢霉属、耳霉属、腐霉属、疫霉属、青霉属、枝孢属、毛霉属、镰孢属、曲霉属、红酵母属、虫霉属、刺孢囊霉属、水霉属的并可产生花生四烯酸的微生物进行突变处理而得到的Δ12去饱和活性低下或缺乏的微生物在培养基中培养,并自培养物提取而得到的。
29.权利要求24-28中任意一项所述的方法,其中所述伴随肝功能障碍的肝脏疾病为急性或慢性肝炎。
30.权利要求24-28中任意一项所述的方法,其中所述伴随肝功能障碍的肝脏疾病为急性肝功能衰竭、肝硬变和/或肝细胞癌。
31.权利要求24-30中任意一项所述的方法,其中所述饮食为功能性食品、营养补助食品、特定的保健用食品或老人用食品。
32.ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物的用途,用于制备对伴随肝功能障碍的肝脏疾病的预防剂或改善剂。
33.权利要求32所述的用途,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的化合物是ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯和/或三酰甘油酯、或者磷脂。
34.权利要求33所述的用途,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是ω-9不饱和脂肪酸相对于组成所述三酰甘油酯的总脂肪酸含有20%或以上。
35.权利要求32-34中任意一项所述的用途,其中所述ω-9不饱和脂肪酸为至少一种选自6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)及5,8,11-二十碳三烯酸(20:3 ω9)的ω-9不饱和脂肪酸。
36.权利要求32-35中任意一项所述的用途,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是通过对属于被孢霉属、耳霉属、腐霉属、疫霉属、青霉属、枝孢属、毛霉属、镰孢属、曲霉属、红酵母属、虫霉属、刺孢囊霉属、水霉属的并可产生花生四烯酸的微生物进行突变处理而得到的Δ12去饱和活性低下或缺乏的微生物在培养基中培养,并自培养物提取而得到的。
37.权利要求32-36中任意一项所述的用途,其中所述伴随肝功能障碍的肝脏疾病为急性或慢性肝炎。
38.权利要求32-36中任意一项所述的用途,其中所述伴随肝功能障碍的肝脏疾病为急性肝功能衰竭、肝硬变和/或肝细胞癌。
39.ω-9不饱和脂肪酸或以ω-9不饱和脂肪酸为组成脂肪酸的化合物的用途,用于制备对伴随肝功能障碍的肝脏疾病具有预防或改善作用的组合物或饮食。
40.权利要求39所述的用途,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的化合物是ω-9不饱和脂肪酸的醇酯、以ω-9不饱和脂肪酸为组成脂肪酸的单酰甘油酯、二酰甘油酯和/或三酰甘油酯、或者磷脂。
41.权利要求40所述的用途,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是ω-9不饱和脂肪酸相对于组成所述三酰甘油酯的总脂肪酸含有20%或以上。
42.权利要求39-41中任意一项所述的用途,其中所述ω-9不饱和脂肪酸为至少一种选自6,9-十八碳二烯酸(18:2 ω9)、8,11-二十碳二烯酸(20:2 ω9)及5,8,11-二十碳三烯酸(20:3 ω9)的ω-9不饱和脂肪酸。
43.权利要求39-42中任意一项所述的用途,其中所述以ω-9不饱和脂肪酸为组成脂肪酸的三酰甘油酯是通过对属于被孢霉属、耳霉属、腐霉属、疫霉属、青霉属、枝孢属、毛霉属、镰孢属、曲霉属、红酵母属、虫霉属、刺孢囊霉属、水霉属的并可产生花生四烯酸的微生物进行突变处理而得到的Δ12去饱和活性低下或缺乏的微生物在培养基中培养,并自培养物提取而得到的。
44.权利要求39-43中任意一项所述的用途,其中所述伴随肝功能障碍的肝脏疾病为急性或慢性肝炎。
45.权利要求39-43中任意一项所述的用途,其中所述伴随肝功能障碍的肝脏疾病为急性肝功能衰竭、肝硬变和/或肝细胞癌。
46.权利要求39-45中任意一项所述的用途,其中所述饮食为功能性食品、营养补助食品、特定的保健用食品或老人用食品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004012207A JP4721642B2 (ja) | 2004-01-20 | 2004-01-20 | 肝障害を伴う肝臓疾患の予防又は改善剤 |
JP012207/2004 | 2004-01-20 | ||
PCT/JP2005/000941 WO2005067914A1 (ja) | 2004-01-20 | 2005-01-19 | 肝障害を伴う肝臓疾患の予防又は改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1842329A true CN1842329A (zh) | 2006-10-04 |
CN1842329B CN1842329B (zh) | 2011-09-14 |
Family
ID=34792369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800008604A Active CN1842329B (zh) | 2004-01-20 | 2005-01-19 | 伴随肝损伤的肝脏疾病的预防剂或改善剂 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8436047B2 (zh) |
EP (1) | EP1707198B1 (zh) |
JP (1) | JP4721642B2 (zh) |
CN (1) | CN1842329B (zh) |
AU (1) | AU2005205662B2 (zh) |
CA (1) | CA2540272C (zh) |
DK (1) | DK1707198T3 (zh) |
WO (1) | WO2005067914A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
JP2012041283A (ja) * | 2010-08-17 | 2012-03-01 | Porien Project Kk | 血管新生抑制剤 |
CN105181832A (zh) * | 2015-08-31 | 2015-12-23 | 广州金域医学检验中心有限公司 | 一种快速检测全血红细胞二十烷二烯酸的方法 |
CN105241969B (zh) * | 2015-08-31 | 2018-03-02 | 西安金域医学检验所有限公司 | 一种快速检测全血红细胞二十二烷四烯酸的方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434101A (en) * | 1981-09-14 | 1984-02-28 | Hoffmann-La Roche Inc. | Inhibitors of SRS-synthesis |
US4432906A (en) * | 1981-09-14 | 1984-02-21 | Hoffmann-La Roche Inc. | Inhibitors of SRS-synthesis |
GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
JPS62195346A (ja) | 1984-11-19 | 1987-08-28 | Sumitomo Pharmaceut Co Ltd | 新規不飽和脂肪酸誘導体 |
JPS6372648A (ja) | 1986-09-16 | 1988-04-02 | Sumitomo Pharmaceut Co Ltd | 新規不飽和脂肪酸誘導体 |
JPH066211Y2 (ja) | 1987-02-24 | 1994-02-16 | トヨタ自動車株式会社 | エンジンの吸気制御装置 |
JPS6426532U (zh) | 1987-08-10 | 1989-02-15 | ||
US5320846A (en) * | 1991-04-17 | 1994-06-14 | New England Deaconess Hospital Corp. | Method and composition for testing patients with metabolic depleting diseases |
US5130147A (en) * | 1991-05-01 | 1992-07-14 | Hannu Karu | Cholesterol lowering colloidal food product containing meat and omega fatty acid and process for preparing |
JP3354582B2 (ja) | 1991-09-30 | 2002-12-09 | サントリー株式会社 | オメガ9系高度不飽和脂肪酸およびこれを含有する脂質の製造方法 |
DE4133694C2 (de) * | 1991-10-11 | 1993-10-07 | Fresenius Ag | Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen |
US5260336A (en) * | 1992-04-30 | 1993-11-09 | New England Deaconess Hospital Corporation | Monounsaturated fat as dietary supplement to minimize the effects of catabolic illness |
JPH0633087A (ja) | 1992-07-17 | 1994-02-08 | Nippon Oil & Fats Co Ltd | 粉末油脂組成物 |
JPH0741421A (ja) | 1993-05-28 | 1995-02-10 | Suntory Ltd | ロイコトリエンb4 (ltb4 )による医学的症状の予防及び改善剤 |
JP3770628B2 (ja) * | 1994-08-09 | 2006-04-26 | サントリー株式会社 | 遅延型アレルギー反応を介する医学的症状の予防及び改善剤 |
CA2201855C (en) * | 1995-08-07 | 2008-11-18 | Satomichi Yoshimura | Preventive or remedy for diseases caused by abnormalities in cartilage tissues |
JP2941787B2 (ja) * | 1997-08-14 | 1999-08-30 | 常盤薬品工業株式会社 | 多価不飽和脂肪酸を含有する医薬組成物および健康食品 |
ATE276768T1 (de) * | 1998-03-24 | 2004-10-15 | Nippon Shinyaku Co Ltd | Arzneimittel gegen hepatitis |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
JP4391673B2 (ja) * | 2000-08-08 | 2009-12-24 | 花王株式会社 | 油脂組成物 |
DE10065123B4 (de) | 2000-12-28 | 2012-12-20 | Robert Bosch Gmbh | Verfahren zur Steuerung einer Diagnose eines Katalysators im Abgas eines Verbrennungsmotors |
CA2452401C (en) * | 2001-07-02 | 2013-02-26 | Suntory Limited | Process for producing fat comprising triglyceride containing highly unsaturated fatty acid |
-
2004
- 2004-01-20 JP JP2004012207A patent/JP4721642B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-19 DK DK05704085.9T patent/DK1707198T3/da active
- 2005-01-19 CN CN2005800008604A patent/CN1842329B/zh active Active
- 2005-01-19 EP EP05704085A patent/EP1707198B1/en not_active Not-in-force
- 2005-01-19 WO PCT/JP2005/000941 patent/WO2005067914A1/ja not_active Application Discontinuation
- 2005-01-19 US US10/562,716 patent/US8436047B2/en active Active
- 2005-01-19 AU AU2005205662A patent/AU2005205662B2/en not_active Ceased
- 2005-01-19 CA CA2540272A patent/CA2540272C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1707198A4 (en) | 2007-03-21 |
DK1707198T3 (da) | 2013-01-28 |
US20060217442A1 (en) | 2006-09-28 |
WO2005067914A1 (ja) | 2005-07-28 |
CA2540272C (en) | 2014-05-27 |
US8436047B2 (en) | 2013-05-07 |
AU2005205662B2 (en) | 2011-05-19 |
JP4721642B2 (ja) | 2011-07-13 |
CA2540272A1 (en) | 2005-07-28 |
EP1707198A1 (en) | 2006-10-04 |
AU2005205662A1 (en) | 2005-07-28 |
EP1707198B1 (en) | 2012-12-19 |
JP2005206476A (ja) | 2005-08-04 |
CN1842329B (zh) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1166652B1 (en) | Utilization of material containing docosapentaenoic acid | |
DE69233556T2 (de) | Arachidonsäure und Verfahren zu ihrer Herstellung sowie Verwendung derselben | |
CN100418519C (zh) | 用于增强认知能力的含有花生四烯酸或其与二十二碳六烯酸的组合的组合物 | |
KR101451415B1 (ko) | 불비누화 물질 함량을 저감시킨 미생물 유지의 제조 방법 및 그 유지 | |
CN1089561C (zh) | 高度不饱和脂肪酸含量高的家禽蛋,其制造方法及其用途 | |
CN1891215A (zh) | 对器质性脑损伤引起的高级脑功能下降具有改善作用的组合物 | |
CN1891214A (zh) | 对白天活动量减少及/或抑郁症状具有改善作用的组合物 | |
KR101245364B1 (ko) | 혈관의 노화에 기인하는 증상 또는 질환을 예방 또는 완화하는 작용이 있는 조성물 | |
CN1842329B (zh) | 伴随肝损伤的肝脏疾病的预防剂或改善剂 | |
KR101192419B1 (ko) | 간장해를 수반하는 간장 질환의 예방 또는 개선제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUNTORY HOLDINGS CO., LTD. Free format text: FORMER OWNER: SUNTORY LTD. Effective date: 20090703 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090703 Address after: Osaka Japan Applicant after: Suntory Holdings Limited Address before: Osaka Japan Applicant before: Suntory Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |